[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610349":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":179,"collaborators":11,"id":181,"slug":182,"hasResults":183,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":11,"eligibilityCriteria":187,"healthyVolunteers":183,"sex":188,"minAge":189,"maxAge":11,"enrollmentInfo":190,"targetDuration":11,"studyType":193,"phases":194,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":211},{"fullName":5,"class":6},"Stemline Therapeutics, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A: MEN2501 Dose Escalation","EXPERIMENTAL",null,[13],"Drug: MEN2501",{"label":15,"type":10,"description":11,"interventionNames":16},"Part B: MEN2501 Dose Expansion & Optimization",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","MEN2501","Oral tablet",[9,15],[24],{"name":25,"affiliation":5,"role":26},"Medical Director","STUDY_DIRECTOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Stemline Trials","CONTACT","1-877-332-7961","cwilliams@menarinistemline.com; MEN2501_StudyTeam@menarinistemline.com",[34,48,58,68,78,88,98,108,120,129,140,149,155,161,170],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":11},"Highlands Oncology Group","RECRUITING","Springdale","Arkansas","72762","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-94.12881,36.18674,{"lat":46,"lon":45},{"facility":49,"status":36,"city":50,"state":51,"zip":52,"country":40,"countryCode":41,"cosmosGeoPoint":53,"geoPoint":57,"contacts":11},"Yale University","New Haven","Connecticut","06519",{"type":43,"coordinates":54},[55,56],-72.92816,41.30815,{"lat":56,"lon":55},{"facility":59,"status":36,"city":60,"state":61,"zip":62,"country":40,"countryCode":41,"cosmosGeoPoint":63,"geoPoint":67,"contacts":11},"Florida Cancer Specialists & Research Institute","Sarasota","Florida","34232",{"type":43,"coordinates":64},[65,66],-82.53065,27.33643,{"lat":66,"lon":65},{"facility":69,"status":36,"city":70,"state":71,"zip":72,"country":40,"countryCode":41,"cosmosGeoPoint":73,"geoPoint":77,"contacts":11},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":43,"coordinates":74},[75,76],-71.05977,42.35843,{"lat":76,"lon":75},{"facility":79,"status":36,"city":80,"state":81,"zip":82,"country":40,"countryCode":41,"cosmosGeoPoint":83,"geoPoint":87,"contacts":11},"Karmanos Cancer Institute","Detroit","Michigan","48201",{"type":43,"coordinates":84},[85,86],-83.04575,42.33143,{"lat":86,"lon":85},{"facility":89,"status":36,"city":90,"state":91,"zip":92,"country":40,"countryCode":41,"cosmosGeoPoint":93,"geoPoint":97,"contacts":11},"Mayo Clinic","Rochester","Minnesota","55905",{"type":43,"coordinates":94},[95,96],-92.4699,44.02163,{"lat":96,"lon":95},{"facility":99,"status":36,"city":100,"state":101,"zip":102,"country":40,"countryCode":41,"cosmosGeoPoint":103,"geoPoint":107,"contacts":11},"NEXT Virginia","Fairfax","Virginia","22031",{"type":43,"coordinates":104},[105,106],-77.30637,38.84622,{"lat":106,"lon":105},{"facility":109,"status":36,"city":110,"state":111,"zip":112,"country":113,"countryCode":114,"cosmosGeoPoint":115,"geoPoint":119,"contacts":11},"Icon Cancer Centre","South Brisbane","Queensland","4101","Australia","AU",{"type":43,"coordinates":116},[117,118],153.02049,-27.48034,{"lat":118,"lon":117},{"facility":121,"status":36,"city":122,"state":11,"zip":123,"country":113,"countryCode":114,"cosmosGeoPoint":124,"geoPoint":128,"contacts":11},"Cancer Research SA","Aberfoyle Park","5000",{"type":43,"coordinates":125},[126,127],138.59163,-35.0768,{"lat":127,"lon":126},{"facility":130,"status":36,"city":131,"state":11,"zip":132,"country":133,"countryCode":134,"cosmosGeoPoint":135,"geoPoint":139,"contacts":11},"Hospital Universitario Dexeus - Grupo Quironsalud","Barcelona","08028","Spain","ES",{"type":43,"coordinates":136},[137,138],2.15899,41.38879,{"lat":138,"lon":137},{"facility":141,"status":36,"city":142,"state":11,"zip":143,"country":133,"countryCode":134,"cosmosGeoPoint":144,"geoPoint":148,"contacts":11},"Clínica Universidad Navarra","Madrid","28027",{"type":43,"coordinates":145},[146,147],-3.70256,40.4165,{"lat":147,"lon":146},{"facility":150,"status":36,"city":142,"state":11,"zip":151,"country":133,"countryCode":134,"cosmosGeoPoint":152,"geoPoint":154,"contacts":11},"Hospital Universitario 12 de Octubre","28041",{"type":43,"coordinates":153},[146,147],{"lat":147,"lon":146},{"facility":156,"status":36,"city":142,"state":11,"zip":157,"country":133,"countryCode":134,"cosmosGeoPoint":158,"geoPoint":160,"contacts":11},"Hospital Universitario HM Sanchinarro","28050",{"type":43,"coordinates":159},[146,147],{"lat":147,"lon":146},{"facility":162,"status":36,"city":163,"state":11,"zip":164,"country":133,"countryCode":134,"cosmosGeoPoint":165,"geoPoint":169,"contacts":11},"Clínica Universidad de Navarra","Pamplona","31008",{"type":43,"coordinates":166},[167,168],-1.64323,42.81687,{"lat":168,"lon":167},{"facility":171,"status":36,"city":172,"state":11,"zip":173,"country":133,"countryCode":134,"cosmosGeoPoint":174,"geoPoint":178,"contacts":11},"Hospital Quironsalud Madrid","Pozuelo de Alarcón","28226",{"type":43,"coordinates":175},[176,177],-3.81338,40.43293,{"lat":177,"lon":176},{"type":180,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610349","phase-1-a-first-in-human-study-of-men2501-in-participants-with-platinum-resistant-ovarian-cancer-100610349",false,"NCT07226427","A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer","A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With Platinum-Resistant Ovarian Cancer","Key Inclusion Criteria:\n\n* Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.\n\nKey Exclusion Criteria:\n\n* Participants with primary platinum-refractory disease.\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria may apply.","FEMALE","18 Years",{"count":191,"type":192},100,"ESTIMATED","INTERVENTIONAL",[195],"PHASE1","This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.",[198],"Platinum-resistant Ovarian Cancer",[20,200,201],"First-in-Human","Ovarian Cancer","2026-07-02",{"date":204,"type":205},"2026-07-06","ACTUAL",{"date":207,"type":205},"2026-01-10",{"date":209,"type":192},"2028-06-02",{"name":5,"class":6},15]